Package leaflet: Information for the user

Oviderm 250 mg/g cream

propylene glycol

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Always use this medicine exactly as described in this leaflet or as your doctor, or pharmacist or nurse have told you.
- Keep this leaflet. You may need to read it again.
- Ask your pharmacist if you need more information or advice.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
- You must talk to a doctor if your symptoms worsen or if they do not improve.

What is in this leaflet

1. What Oviderm is and what it is used for

Oviderm is an emollient cream containing the active substance propylene glycol (25%). Propylene glycol has water-binding properties and some antimicrobial effect, on certain bacteria and fungae.

Oviderm is used for the treatment of dry skin in adults and children.

2. What you need to know before you use Oviderm

Do not use Oviderm:
- if you are allergic to propylene glycol or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Do not apply Oviderm
-on burned skin
-in the ear canal since propylene glycol might cause damage to the ear

Pregnancy and breast-feeding

There are no known risks during pregnancy.

Do not use Oviderm on or around the nipples when breast-feeding in order to avoid unnecessary ingestion by the child.

Oviderm contains cetostearyl alcohol
May cause local skin reactions (e.g. contact dermatitis).

3. How to use Oviderm

Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse have told you. Check with your doctor, pharmacist or nurse if you are not sure.

Adults and children
The cream should be applied on the skin when needed, preferably several times daily, and always after contact with water. Apply as much as the skin can absorb without feeling sticky.

How to activate the pump:
The pump is pressed down quickly several times during the first use.
Repeat until the cream comes out.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common: may affect up to 1 in 10 people
- Transient smarting, itching, stinging and redness of the skin.
- Allergic reactions.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Oviderm

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the tube and carton or the container after EXP. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Oviderm contains

- The active substance is propylene glycol. 1 gram cream contains 250 mg propylene glycol.
- The other ingredients are coconut oil, cetostearyl alcohol, stearid acid, macrogol stearate, glycerol monostearate, sodium citrate, anhydrous citric acid, purified water.

What Oviderm looks like and contents of the pack
Oviderm is a white odourless cream. It is available in a plastic tube (100 g) or a plastic container with a pump (500 g) or a Twin pack 600 g containing, plastic container with a pump (500 g) + plastic tube (100 g).
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Galenica AB
P A Hanssons väg 41

205 12 Malmö
Sweden

Manufacturer
Bioglan AB
Borrgatan 31
211 24 Malmö
Sweden

(Twin pack only)
Galenica AB
P A Hanssons väg 41
205 12 Malmö
Sweden

This medicinal product is authorised in the Member States of the EEA under the following names:

This leaflet was last revised in 15 June 2026